Janux Therapeutics to Present Virtually at Upcoming Investor Conferences

SAN DIEGO–(BUSINESS WIRE)–Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will participate in fireside chats at two upcoming virtual investor conferences: Cowen’s 5th Annual IO Next Summit Forum: Fireside Chat Date: Monday, November 15
Click here to view original post